Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients with Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis
ConclusionsConsidering MACEs, myocardial infarction, all kinds of stroke, ischemic stroke, and major bleeding, low-dose aspirin plus rivaroxaban 2.5 mg twice daily should be considered the preferred regimen for S-ASCVD patients with low bleeding risk.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Aspirin | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Databases & Libraries | Heart | Heart Attack | Ischemic Stroke | Plavix | Stroke | Study